Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Accounts Payables: 2020-2024

Historic Accounts Payables for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to $64.8 million.

  • Tarsus Pharmaceuticals' Accounts Payables rose 89.75% to $103.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.5 million, marking a year-over-year increase of 89.75%. This contributed to the annual value of $64.8 million for FY2024, which is 173.48% up from last year.
  • As of FY2024, Tarsus Pharmaceuticals' Accounts Payables stood at $64.8 million, which was up 173.48% from $23.7 million recorded in FY2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Accounts Payables peaked at $64.8 million during FY2024, and registered a low of $4.3 million during FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $23.7 million (2023), whereas its average is $32.8 million.
  • Data for Tarsus Pharmaceuticals' Accounts Payables shows a peak YoY skyrocketed of 173.48% (in 2024) over the last 5 years.
  • Over the past 5 years, Tarsus Pharmaceuticals' Accounts Payables (Yearly) stood at $4.3 million in 2020, then spiked by 99.68% to $8.7 million in 2021, then rose by 14.17% to $9.9 million in 2022, then soared by 139.06% to $23.7 million in 2023, then skyrocketed by 173.48% to $64.8 million in 2024.